Results 31 to 40 of about 18,687 (213)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection

European Journal of Medical Research, 2009
Multiclass-drug resistance, often caused by poor treatment compliance, is a challenging problem in all categories of HIV-infected patients. Selective pressure is higher in youth for both biological and behavioral reasons.
Rosso R, Bernardini C, Bruzzone B, Secondo G, Icardi G, Viscoli C, Di Biagio A   +6 more
doaj   +1 more source

Mass spectrometry captures off-target drug binding and provides mechanistic insights into the human metalloprotease ZMPSTE24. [PDF]

, 2016
Off-target binding of hydrophobic drugs can lead to unwanted side effects, either through specific or non-specific binding to unintended membrane protein targets.
Carpenter, Elisabeth P, Gault, Joseph, Marcoux, Julien, Mehmood, Shahid, Michaelis, Susan, Quigley, Andrew, Robinson, Carol V, Young, Stephen G   +7 more
core   +2 more sources

A novel simultaneous high performance liquid chromatography-PDA method for the determination of Tenofovir AF, Darunavir, Emtricitabine and Cobicistat in bulk and its application to marketed formulation

Future Journal of Pharmaceutical Sciences, 2022
Background The present research article involves the simultaneous determination of Tenofovir alafenamide, Darunavir, Emtricitabine and Cobicistat in bulk as well as in tablet dosage form using high performance liquid chromatography. Result The separation
Challamalla Pavani, E. Susithra
doaj   +1 more source

Development and validation of UV-spectrophotometry method for quantitative determination of amorphous darunavir

Разработка и регистрация лекарственных средств
Introduction. Darunavir as an effective antiretroviral drug is widely used in clinical practice, including for the treatment of pediatric patients, as well as pregnant women, and for personalized therapy.
M. A. Mandrik, I. A. Sadkovskii, E. D. Pinegina, L. A. Korol, I. I. Krasnuk   +4 more
doaj   +1 more source

The structural, dynamic, and thermodynamic basis of darunavir resistance of a heavily mutated HIV-1 protease using molecular dynamics simulation

Frontiers in Molecular Biosciences, 2022
The human immunodeficiency virus type 1 protease (HIV-1 PR) is an important enzyme in the life cycle of the HIV virus. It cleaves inactive pre-proteins of the virus and changes them into active proteins. Darunavir (DRV) suppresses the wild-type HIV-1 PR (
Yaser Shabanpour, Sharareh Sajjadi, Esmaeil Behmard, Parviz Abdolmaleki, Amir Homayoun Keihan   +4 more
doaj   +1 more source

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]

, 2019
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan, Carrero, Ana, Crespo, Manuel, González García, Juan, Guardional, Josep M., Gómez, Julián, Jiménez Sousa, María Angeles, Martínez, Isidoro, Resino, Salvador, Santos, Ignacio de los, The GESIDA 3603b Cohort Study Group, Vigón, Lorena, Von Wichmann, Miguel A., Vázquez Morón, Sonia, Yélamos, María Belén   +14 more
core   +5 more sources

Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1

HIV Research & Clinical Practice, 2021
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Objective
Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups   +10 more
doaj   +1 more source

Servicio de dispensación: interacción entre darunavir y quetiapina

Farmacéuticos Comunitarios, 2022
Paciente varón de 52 años, con síndrome metabólico, virus de inmunodeficiencia humana (VIH), insomnio, trastorno de ansiedad generalizada, esquizofrenia y con medicación analgésica, que viene sufriendo numerosos episodios nocturnos de insomnio e ...
Damià Barris Blundell , Octavio Carrasco Naranjo   +1 more
doaj   +1 more source

Highlights from the 24th conference on retroviruses and opportunistic infections, 13-16 February 2017, Seattle, Washington, USA [PDF]

, 2017
From the 13th to 16th February 2017, researchers from around the world convened for the 24th annual Conference on Retroviruses and Opportunistic Infections (CROI) at the Washington State Convention Center in Seattle, Washington.
Bhagani, Sanjay, Colby, Donn J, Crowell, Trevor A, Gathogo, Esther N, Hill, Andrew, Hsu, Denise, Kinloch, Sabine, Lyall, Hermione, Malatinková, Eva, Polyak, Christina, Psomas, Christina, Trypsteen, Wim, Vandekerckhove, Linos   +12 more
core   +5 more sources

Safety and Effectiveness of Glecaprevir/Pibrentasvir in Children and Adolescents With Chronic Hepatitis C: Reports From All‐Case Post‐Marketing Surveillance in Japan

Hepatology Research, EarlyView.
ABSTRACT Aim The aim of this all‐case post‐marketing study was to evaluate the real‐world safety and effectiveness in all children and adolescents with chronic hepatitis C with or without compensated cirrhosis treated with glecaprevir/pibrentasvir (G/P) in Japan. Methods This prospective, observational post‐marketing surveillance study was conducted at
Tatsuki Mizuochi, Katsuyoshi Kawana, Mariko Kobayashi, Eri Iwashita, Itaru Iwama, Daiki Abukawa, Hitoshi Tajiri   +6 more
wiley   +1 more source